Background: Precise mechanisms underlying the pathophysiology of autism are currently unknown. Given the major role of glutamate in brain development, we have hypothesized that glutamatergic neurotransmission plays a role in the pathophysiology of autism. In this study, we studied whether amino acids (glutamate, glutamine, glycine, D-serine, and L-serine) related to glutamatergic neurotransmission are altered in serum of adult patients with autism. Methods: We measured serum levels of amino acids in 18 male adult patients with autism and age-matched 19 male healthy subjects using highperformance liquid chromatography. Results: Serum levels (mean = 89.2 μM, S.D. = 21.5) of glutamate in the patients with autism were significantly (t = − 4.48, df = 35, p < 0.001) higher than those (mean = 61.1 μM, S.D. = 16.5) of normal controls. In contrast, serum levels of other amino acids (glutamine, glycine, D-serine, L-serine) in the patients with autism did not differ from those of normal controls. There was a positive correlation (r = 0.523, p = 0.026) between serum glutamate levels and Autism Diagnostic Interview-Revised (ADI-R) social scores in patients. Conclusions: The present study suggests that an abnormality in glutamatergic neurotransmission may play a role in the pathophysiology of autism.
Autism is a neuropsychiatric disorder characterized by severe and sustained impairment in social interaction, deviance in communication, and patterns of behavior and interest that are restricted, stereotyped, or both (Volkmar and Pauls, 2003) . Although genetic and environmental factors are implicated in the pathophysiology of autism, the precise mechanisms underlying the pathophysiology of this disorder remain to be determined (Volkmar and Pauls, 2003; Baron-Cohen and Belmonte, 2005; Polleux and Lauder, 2004; McDougle et al., 2005 ).
Glutamate, the major excitatory neurotransmitter in the brain, plays a major role in brain development, affecting neuronal migration, neuronal differentiation, axon genesis, and neuronal survival (Coyle et al., 2002) . Accumulating evidence suggests that abnormalities in glutamatergic neurotransmission may play a role in the pathophysiology of autism (McDougle et al., 2005) . First, cDNA microarray technology has demonstrated that the glutamate neurotransmitter system is abnormal in postmortem brain samples of autism (Purcell et al., 2001 ). The mRNA levels of genes, including excitatory amino acid transporter 1 (EAAT 1) and AMPA-type glutamate receptor, are significantly increased in the brain of autism, suggesting abnormalities of glutamatergic neurotransmission in the pathogenesis of this disorder (Purcell et al., 2001 
